Differential inhibition of plasma versus tissue ace by utibapril: Biochemical and functional evidence for inhibition of vascular ACE activity

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 5, 1997, Pages 684-691

  Buikema, Hendrik ^a   Pinto, Yigal M ^a   Van Geel, Peter Paul ^a   Rooks, Gerrit ^a   De Langen, Cees D J ^a   De Graeff, Pieter A ^a   Van Gilst, Wiek H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE inhibitor; Angiotensin I and II; Isolated aorta; Isolated heart; Normotensive rats

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UTIBAPRIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; ISOLATED HEART; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, THORACIC; CORONARY CIRCULATION; HEART; HEMODYNAMIC PROCESSES; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PEPTIDYL-DIPEPTIDASE A; PRODRUGS; RATS; RATS, WISTAR; THIADIAZOLES; VASOCONSTRICTOR AGENTS;

EID: 0031010260     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199705000-00018     Document Type: Article

References (33)

1. Cushmann D, Ondetti M. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991;17:589-92.
2. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
3. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
4. Miyazaki M, Okamura T, Okunishi H, Toda N. Vascular angiotensin converting enzyme in the development of renal hypertension. J Cardiovasc Pharmacol 1986;8(suppl 10):S58-61.
5. Schieffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
6. Wollert KC, Studer R, von-Bulow B, Drexler H. Survival after myocardial infarction in the rat: role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90(5):2457-67.
7. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8:553-9.
8. Bader M, Zhao Y, Sander M, et al. Role of tissue renin in the pathophysiology of hypertension in TGR(mRen2)27 rats. Hypertension 1992;19:681-6.
9. Harrap SB. Genetics of coronary disease: beginning the long journey [Commentary]. Lancet 1994;344:901-2.
10. Urata H, Kinoshita A, Misono KS, Bumpus EM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265: 22348-57.
11. Carr RD, Cooper AE, Hutchinson R, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol 1990;100:90-4.
12. Carr RD, Killingback PG, Higgs L, et al. Differences in tissue ACE-inhibitory profile between FPL 63547 and enalapril after chronic dosing to spontaneously hypertensive rats. Br J Pharmacol 1990;99:17P.
13. van Gilst WH, de Graeff PA, de Leeuw MJ, Scholtens E, Wesseling H. Converting enzyme inhibitors and the role of sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. J Cardiovasc Pharmacol 1991;18:429-36.
14. Pinto YM, de Smet BGJL, van Gilst WH, et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-8.
15. Kroon AA, Stalenhoef AFH, Buikema H, et al. The effect of cholesterol reduction on the endothelial function and the progression of atherosclerosis in WHHL rabbits. Atherosclerosis 1993;103: 221-30.
16. Buikema H, Grandjean JG, van den Broek S, van Gilst WH, Lie KI, Wesseling H. Differences in vasomotor control between human gastroepiploic and left internal mammary artery. Circulation 1992;86(suppl II):11205-9.
17. Buikema H, van Gilst WH, van Veldhuisen DJ, et al. Endothelium dependent relaxation in two different models chronic heart failure and the effect of ibopamine. Cardiovasc Res 1993;27:2118-24.
18. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-82.
19. Eglème C, Cressier F, Wood JM. Local formation of angiotensin II in rat aorta: effect of endothelium. Br J Pharmacol 1990; 100:227-40.
20. Pipili E, Manolopoulos VG, Catravas JD, Maragoudakis ME. Angiotensin-converting enzyme activity is present in the endothelium-denuded aorta. Br J Pharmacol 1989;98:333-5.
21. Pinto YM, Buikema H, van Gilst WH. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. Clin Exp Hypertens 1995;17(3): 441-68.
22. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzymes is related to phenotypic differences in human arteries. Eur Heart J 1996;17:787-94.
23. Auch-Schwelk W, Duske E, Hink U, Betz M, Unkelbach M, Fleck E. Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension 1994;23:832-7.
24. Regitz-Zagrosek V, Auch-Schwelk W, Hess B, et al. Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists. J Cardiovasc Pharmacol 1995;26: 66-72.
25. Mombouli JV, Nephtali M, Vanhoutte PM. Effects of the non-sulfhydryl angiotensin I converting enzyme inhibitor cilazaprilat on endothelium-dependent responses in isolated canine arteries. Hypertension 1991;18(suppl II):1122-9.
26. Okunishi H, Shiota N, Kawanoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathway: human versus rodents. Jpn J Pharmacol 1993;62:207-10.
27. Auch-Schwelk W, Bossaler C, Claus M, Graf K, Gräfe M, Fleck E. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol 1992;20(suppl 9):S62-7.
28. Schrör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20(suppl 9):S68-73.
29. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992;20(suppl 9):S74-83.
30. Gohlke P, Linz W, Schölkens BA, et al. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 1994;23:411-8.
31. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. Hypertension 1989;7(suppl 5):S11-6.
32. Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn FAO. Localization of angiotensin-converting enzyme in the rat heart. Circ Res 1991;68:141-9.
33. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989;A11(7): 1325-50.